New global Phase 1 data from a randomized dose-expansion cohort of iza-bren in previously treated EGFR-mutated metastatic NSCLC demonstrate promising antitumor activity and a tolerable safety proﬁle, supporting selection of 2.5 mg/kg D1D8 Q3W as the recommended Phase 3 dose

izalontamab brengitecan (BL-B01D1) - Sichuan Biokin Pharmaceutical, BMS, Systimmune

Sep 12, 2026